

Amendments to the Claims:

This claim listing replaces all prior versions, and listings of claims in the application.
Please amend the claims as follows:

1. (Currently amended) ~~Compounds~~ A compound of the general formula



(I)

wherein



is ^DPro-^LPro or ^LPro-^DPro and wherein the amino acid residues in chain Z are:

-P1: Leu; Thr; or Arg;

-P2: Arg; or Trp;

-P3: Leu;

-P4: Lys; hArg [L-homo-arginine]; (BA)G [N-(4-amino-n-butyl)glycine]; or Gln;

-P5: Lys; Gln; hArg; or (PeA)G [N-(5-amino-n-pentyl)glycine];

-P6: Arg, Trp, hArg; (EGU)G [N-(2-guanidinoethyl)glycine]; (EA)G [N-(2-aminoethyl)glycine]; (PrA)G [N-(3-aminopropyl)glycine]; (PeA)G or (BA)G;

-P7: Arg; (PeA)G; or Val;

-P8: Trp; or Bip [L-(4-phenyl)phenylalanine];

-P9: Lys; Arg; or hArg;

-P10: Tyr;

-P11: Arg; or Tyr; and

-P12: Val; or Arg;

with the proviso that


- the amino acid residue in P4 is (BA)G; and/or

- the amino acid residue in P5 is (PeA)G; and/or


- the amino acid residue in P6 is (EGU)G or
 (EA)G or (PrA)G or (PeA)G or (BA)G; and/or

- the amino acid residue in P7 is (PeA)G.

a group of one of the formulae






wherein




is the residue of an L- α -amino acid with B being a residue of formula $-\text{NR}^{20}\text{CH}(\text{R}^{71})-$ or the enantiomer of one of the groups A1 to A69 as defined hereinafter;



is a group of one of the formulae





—A82— A83—

R^1 is—H; lower alkyl; or aryl-lower alkyl;

R^2 is—H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_nOR^{55}$; $-(CH_2)_m(CHR^{61})_nSR^{56}$;
 $-(CH_2)_m(CHR^{61})_nNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_nOCONR^{33}R^{82}$;
 $-(CH_2)_m(CHR^{61})_nNR^{20}CONR^{33}R^{82}$; $-(CH_2)_n(CHR^{61})_nCOOR^{57}$;
 $-(CH_2)_n(CHR^{61})_nCONR^{58}R^{59}$; $-(CH_2)_n(CHR^{61})_nPO(OR^{60})_2$;
 $-(CH_2)_n(CHR^{61})_nSO_2R^{62}$; or $-(CH_2)_n(CHR^{61})_nC_6H_4R^8$;

R^3 is—H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_nOR^{55}$; $-(CH_2)_m(CHR^{61})_nSR^{56}$;
 $-(CH_2)_m(CHR^{61})_nNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_nOCONR^{33}R^{82}$;
 $-(CH_2)_m(CHR^{61})_nNR^{20}CONR^{33}R^{82}$; $-(CH_2)_n(CHR^{61})_nCOOR^{57}$;
 $-(CH_2)_n(CHR^{61})_nCONR^{58}R^{59}$; $-(CH_2)_n(CHR^{61})_nPO(OR^{60})_2$;
 $-(CH_2)_n(CHR^{61})_nSO_2R^{62}$; or $-(CH_2)_n(CHR^{61})_nC_6H_4R^8$;

R^4 is—H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_nOR^{55}$; $-(CH_2)_m(CHR^{61})_nSR^{56}$;
 $-(CH_2)_m(CHR^{61})_nNR^{33}R^{34}$;
 $-(CH_2)_m(CHR^{61})_nOCONR^{33}R^{82}$; $-(CH_2)_m(CHR^{61})_nNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_p(CHR^{61})_pCOOR^{57}$; $-(CH_2)_p(CHR^{61})_pCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_pPO(OR^{60})_2$;
 $-(CH_2)_p(CHR^{61})_pSO_2R^{62}$; or $-(CH_2)_n(CHR^{61})_nC_6H_4R^8$;

R^5 is—alkyl; alkenyl; $-(CH_2)_n(CHR^{61})_nOR^{55}$; $-(CH_2)_n(CHR^{61})_nSR^{56}$; $-(CH_2)_n(CHR^{61})_nNR^{33}R^{34}$;
 $-(CH_2)_n(CHR^{61})_nOCONR^{33}R^{82}$; $-(CH_2)_n(CHR^{61})_nNR^{20}CONR^{33}R^{82}$;
 $-(CH_2)_n(CHR^{61})_nCOOR^{57}$; $-(CH_2)_n(CHR^{61})_nCONR^{58}R^{59}$; $-(CH_2)_n(CHR^{61})_nPO(OR^{60})_2$;
 $-(CH_2)_n(CHR^{61})_nSO_2R^{62}$; or $-(CH_2)_n(CHR^{61})_nC_6H_4R^8$;


Applicants: Vrijbloed et al.


Application No. 10/530,335


Amendment and Response dated March 12, 2010

Reply to Office Action of November 12, 2009

Page 6







R^{57} is—H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;

R^{58} is—H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; or heteroaryl lower alkyl;

R^{59} is—H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; or heteroaryl lower alkyl; or

R^{58} and R^{59} taken together can form: $-(\text{CH}_2)_{2-6}$; $-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2$; $-(\text{CH}_2)_2\text{S}(\text{CH}_2)_2$; or $-(\text{CH}_2)_2\text{NR}^{57}(\text{CH}_2)_2$;

R^{60} is—H; lower alkyl; lower alkenyl; aryl; or aryl lower alkyl;


R^{61} is—alkyl; alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl lower alkyl; $-(\text{CH}_2)_m\text{OR}^{55}$; $-(\text{CH}_2)_m\text{NR}^{33}\text{R}^{24}$; $-(\text{CH}_2)_m\text{OCONR}^{76}\text{R}^{82}$; $-(\text{CH}_2)_m\text{NR}^{20}\text{CONR}^{78}\text{R}^{82}$; $-(\text{CH}_2)_o\text{COOR}^{57}$; $-(\text{CH}_2)_o\text{NR}^{58}\text{R}^{59}$; or $-(\text{CH}_2)_o\text{PO}(\text{COR}^{60})_2$;

R^{62} is—lower alkyl; lower alkenyl; aryl; heteroaryl; or aryl lower alkyl;

R^{63} is—H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl lower alkyl; COR^{64} ; COOR^{57} ; $\text{CONR}^{58}\text{R}^{59}$; SO_2R^{62} ; or $\text{PO}(\text{OR}^{60})_2$;

R^{34} and R^{62} taken together can form: $-(\text{CH}_2)_{2-6}$; $-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2$; $-(\text{CH}_2)_2\text{S}(\text{CH}_2)_2$; or $-(\text{CH}_2)_2\text{NR}^{57}(\text{CH}_2)_2$;

R^{64} is—H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl lower alkyl;














R^{65} is—H; lower alkyl; lower alkenyl; aryl; aryl lower alkyl; heteroaryl lower alkyl; COR^{57} ; COOR^{57} ; or $\text{CONR}^{58}\text{R}^{59}$;

R^{66} is—H; lower alkyl; lower alkenyl; aryl; aryl lower alkyl; heteroaryl lower alkyl; or $\text{CONR}^{58}\text{R}^{59}$;

m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is 0 or 1;

Z is a chain of 12 α -amino acid residues, the positions of said amino acid residues in said chain being counted starting from the N-terminal amino acid, whereby these amino acid residues are, depending on their position in the chains, Gly, or Pro, or of formula $-A-CO-$, or of formula $-B-CO-$, or of one of the types






R⁷⁵ is lower alkyl; lower alkenyl; or aryl lower alkyl;


R³³ and R⁷⁵ taken together can form: $-(\text{CH}_2)_{2-6};-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2;-(\text{CH}_2)_2\text{S}(\text{CH}_2)_2;\text{or}$
 $-(\text{CH}_2)_2\text{NR}^{67}(\text{CH}_2)_2;$

R⁷⁵ and R⁸² taken together can form: $-(\text{CH}_2)_{2-6};-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2;-(\text{CH}_2)_2\text{S}(\text{CH}_2)_2;\text{or}$
 $-(\text{CH}_2)_2\text{NR}^{67}(\text{CH}_2)_2;$

R⁷⁶ is H; lower alkyl; lower alkenyl; aryl lower alkyl; $(\text{CH}_2)_o\text{OR}^{72};(\text{CH}_2)_o\text{SR}^{72};$
 $(\text{CH}_2)_o\text{NR}^{33}\text{R}^{34};-(\text{CH}_2)_o\text{OCONR}^{33}\text{R}^{75};-(\text{CH}_2)_o\text{NR}^{20}\text{CONR}^{33}\text{R}^{82};$
 $(\text{CH}_2)_o\text{COOR}^{75};-(\text{CH}_2)_o\text{CONR}^{58}\text{R}^{50};-(\text{CH}_2)_o\text{PO}(\text{OR}^{60})_2;-(\text{CH}_2)_p\text{SO}_2\text{R}^{60};\text{or}$
 $(\text{CH}_2)_o\text{COR}^{64};$

R⁷⁷ is phenyl, p-hydroxyphenyl, 2-naphthyl, 1-naphthyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3,4-dichlorophenyl, 4-fluorophenyl, 3-fluorophenyl, 2-fluorophenyl, p-benzoyloxyphenyl, p-biphenyl or p-benzoylphenyl or a heteroaryl group of one of the formulae





R^{78} is H; lower alkyl; aryl; or aryl-lower alkyl;

R^{78} and R^{82} taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or
 $-(CH_2)_2NR^{57}(CH_2)_2-$;

R^{79} is H; lower alkyl; aryl; or aryl-lower alkyl; or

R^{78} and R^{79} taken together, can be $-(CH_2)_{2-7}-$; $-(CH_2)_2O(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

R^{80} is H; or lower alkyl;

R^{81} is H; lower alkyl; or aryl-lower alkyl;

R^{82} is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;

R^{33} and R^{83} taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or
 $-(CH_2)_2NR^{82}(CH_2)_2-$;

R^{83} is H; lower alkyl; aryl; or $NR^{78}R^{79}$;

R^{84} is $-(CH_2)_m(CHR^{61})_nOR^{78}$; $-(CH_2)_m(CHR^{61})_nSR^{78}$; $-(CH_2)_pCONR^{78}R^{79}$;—
 $-(CH_2)_pNR^{80}CONR^{78}R^{79}$;

— $-(CH_2)_pC_6H_4CONR^{78}R^{79}$; or $-(CH_2)_pC_6H_4NR^{80}CONR^{78}R^{79}$;

R^{85} is lower alkyl; or lower alkenyl;

R^{86} is R^{74} ; $[(CH_2)_uX]_t(CH_2)_vNR^{78}R^{79}$; $[(CH_2)_uX]_t(CH_2)_vC(=NR^{80})NR^{78}R^{79}$; X is O,
 NR^{20} , S, OCOO, u is 1-3, t is 1-6, v is 1-3;

R^{87} is R^{84} ; $[(CH_2)_uX]_t(CH_2)_vOR^{78}$; $[(CH_2)_uX]_t(CH_2)_vCONR^{78}R^{79}$; $[(CH_2)_uX]_t(CH_2)_v$
 $NR^{80}CONR^{78}R^{79}$; $[(CH_2)_uX]_t(CH_2)_vSR^{78}$; X is O, NR^{20} , S, OCOO, u is 1-3, t is
 1-6, v is 1-3;

with the proviso that in said chain of 12 α -amino acid residues Z the amino acid residues in
 positions 1 to 12 are:

- P1: — of type C or of type D or of type E or of type F, or the residue is Pro;
- P2: — of type E or of type D;
- P3: — of type C, or the residue is Pro;

~~— P4: — of type E or of type F or of type I or of type K;~~
~~— P5: — of type E or of type D or of type C or of type I or of type K or of type F;~~
~~— or the residue is Gly or Pro;~~
~~— P6: — of type E or of type F or of formula —A—CO—, or of type I or of type K or of~~
~~— type D, or the residue is Gly;~~
~~— P7: — of type E or of type F or of type I or of type C or of formula —B—CO—;~~
~~— P8: — of type D or of type C, or the residue is Pro;~~
~~— P9: — of type E or of type D or of type F;~~
~~— P10: — of type D or of type C or the residue is Pro;~~
~~— P11: — of type E or of type D or of type C; and~~
~~— P12: — of type C or of type D or of type E or of type F, or the residue is Pro; or~~
~~— P4 and P9 and/or P2 and P11, taken together, can form a group of type H; and at~~
~~— P6 and P7 also D isomers being possible;~~
with the further proviso that said chain of 12 α -amino acid residues contains at least one residue
of type I or of type K;

and or a pharmaceutically acceptable salts thereof.

2-9. (Previously cancelled)

10-13. (Cancelled)

14-15. (Previously cancelled)

16-17. (Cancelled)

18. (Currently amended) ~~A~~ The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (EA)G;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

19. (Currently amended) ~~A~~ The compound of formula Ia according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: hArg;
- P5: hArg;
- P6: (EGU)G;
- P7: Arg;
- P8: Trp;
- P9: hArg;
- P10: Tyr;

- P11: Arg; and
- P12: Val.

20. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (PrA)G;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

21. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro; and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (BA)G;
- P7: Arg;

- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

22. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: (BA)G;
- P5: Lys;
- P6: (BA)G;
- P7: Arg;
- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

23. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;

- P5: Lys;
- P6: (PrA)G;
- P7: Arg;
- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

24. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: Arg;
- P7: (PeA)G;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Val.

25. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;

- P2: Trp;
- P3: Leu;
- P4: Gln;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

26. (Currently amended) A The compound of formula 1 according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and

- P12: Val.

27. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

P1: Thr;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
P12: Arg.

28. (Currently amended) A The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Gln;
- P5: Lys;
- P6: Arg;
- P7: (PeA)G;
- P8: Trp;

- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

29. (Currently amended) ~~A~~ The compound of formula I according to claim 1 wherein the template is ^DPro-^LPro and the amino acid residues in position 1 – 12 are:

- P1: Thr;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

30. (Currently amended) ~~Enantiomers~~ An enantiomer of ~~the a~~ compounds of formula I as defined in claim 1.


31-32. (Cancelled)

33. (Previously presented) A pharmaceutical composition containing a compound according to claim 1 and a pharmaceutically inert carrier.

34. (Currently amended) ~~Compositions~~ A composition according to claim 33 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.
35. (Currently amended) ~~Compositions~~ A composition according to claim 33 in form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
36. (Withdrawn) A method for treating or preventing infections or diseases related to such infections, which comprises administering to a patient in need of such treatment or prevention an effective amount of a compound according to claim 1.
37. (Withdrawn) A method for disinfecting or preserving foodstuffs, cosmetics, medicaments and other nutrient-containing materials which comprises adding to such foodstuffs, cosmetics, medicaments and other nutrient-containing materials an effective amount of a compound according to claim 1.
38. (Withdrawn) A process for the manufacture of compounds according to claim 1 which process comprises
- (a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 5, 6 or 7, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
 - (b) removing the N-protecting group from the product thus obtained;
 - (c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid

residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (d) removing the N-protecting group from the product thus obtained;
- (e) repeating steps (c) and (d) until the N-terminal amino acid residue has been introduced;
- (f) coupling the product thus obtained with a compound of the general formula



wherein



is as defined above and X is an N-protecting group or, if



is to be group (a1) or (a2), above, alternatively

- (fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula



wherein B and A are as defined above, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;


- (fb) removing the N-protecting group from the product thus obtained; and

- (fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (g) removing the N-protecting group from the product obtained in step (f) or (fc);
- (h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (i) removing the N-protecting group from the product thus obtained;
- (j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (k) removing the N-protecting group from the product thus obtained;
- (l) repeating steps (j) and (k) until all amino acid residues have been introduced;
- (m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (o) detaching the product thus obtained from the solid support;
- (p) cyclizing the product cleaved from the solid support;
- (q) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (r) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;
- (s) if desired guanidinyllating any side-chain amino group present in the chain of amino acid residues; and

(t) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.

39. (Withdrawn) A process for the manufacture of compounds according to claim 1 which process comprises

(a') coupling an appropriately functionalized solid support with a compound of the general formula



wherein



is as defined above and X is an N-protecting group or, if



is to be group (a1) or (a2), above, alternatively

(a'a) coupling said appropriately functionalized solid support with an appropriately N-protected derivative of an amino acid of the general formula



III

or



IV

wherein B and A are as defined above, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (a'b) removing the N-protecting group from the product thus obtained; and
- (a'c) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (b') removing the N-protecting group from the product obtained in step (a') or (a'c);
- (c') coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (d') removing the N-protecting group from the product thus obtained;
- (e') coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (f') removing the N-protecting group from the product thus obtained;
- (g') repeating steps (e') and (f') until all amino acid residues have been introduced;
- (h') if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (i') detaching the product thus obtained from the solid support;
- (j') cyclizing the product cleaved from the solid support;
- (k') if desired forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (l') removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;

(m') if desired guanidinylation any side-chain amino group present in the chain of amino acid residues; and

(n') if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.

40. (Withdrawn) A process according to claim 38 but wherein an amino acid residue of type I or K is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula H_2NR^{86} and, respectively, H_2NR^{87} which, if necessary, is appropriately protected.

41. (Withdrawn) A process according to claim 40 wherein said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.

42. (Withdrawn) A modification of the process according to claim 38 for the manufacture of compounds according to claim 30 in which enantiomers of all chiral starting materials are used.

43. (Withdrawn) A process according to claim 39 but wherein an amino acid residue of type I or K is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula H_2NR^{86} and, respectively, H_2NR^{87} which, if necessary, is appropriately protected.

44. (Withdrawn) A process according to claim 43 wherein said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.

45. (Withdrawn) A modification of the process according to claim 39 for the manufacture of compounds according to claim 30 in which enantiomers of all chiral starting materials are used.

Applicants: Vrijbloed et al.
Application No. 10/530,335
Amendment and Response dated March 12, 2010
Reply to Office Action of November 12, 2009
Page 28

46. (Withdrawn) A method according to claim 36 wherein said disease is Cystic Fibrosis.